UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Volltextzugriff (PDF)

Editorial: Therapies and influences in urothelial carcinoma

Frontiers in oncology, 2022-12, Vol.12, p.1126494-1126494

2022

Volltextzugriff (PDF)

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2481-2488

2017

Volltextzugriff (PDF)

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of oncology, 2012-01, Vol.23 (1), p.53-58

2012

Volltextzugriff (PDF)

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Investigational new drugs, 2015-08, Vol.33 (4), p.969-976

2015

Volltextzugriff (PDF)

Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Annals of oncology, 2018-10, Vol.29, p.viii323-viii324

2018

Volltextzugriff (PDF)

Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis

Current oncology (Toronto), 2019-04, Vol.26 (2), p.e260-265

2019

Volltextzugriff (PDF)

2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

European journal of cancer (1990), 2015-09, Vol.51, p.S525-S525

2015

Volltextzugriff (PDF)

The Future of Systemic Therapies for Localised Prostate Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-08, Vol.25 (8), p.506-513

2013

Volltextzugriff (PDF)

Stereotactic navigation versus ultrasound guidance in placing IRE applicators in a liver phantom

Scientific reports, 2021-10, Vol.11 (1), p.21031-21031, Article 21031

2021

Volltextzugriff (PDF)

Palliative Radiotherapy Improves Pain and Reduces Functional Interference in Patients with Painful Bone Metastases: A Quality Assurance Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2006-09, Vol.18 (7), p.539-544

2006

Volltextzugriff (PDF)

PO-1205: Small cell carcinoma of the bladder: Retrospective long-term outcomes of chemoradiation

Radiotherapy and oncology, 2020-11, Vol.152, p.S635-S635

2020

Volltextzugriff (PDF)

Utilization of Radiotherapy for Palliation of Bone Metastases: A 3-Year Patterns of Practice Study at a Regional Cancer Centre

International journal of radiation oncology, biology, physics, 2007-11, Vol.69 (3), p.S93-S94

2007

Volltextzugriff (PDF)

Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371

Annals of oncology, 2017-09, Vol.28, p.v325-v325

2017

Volltextzugriff (PDF)

983PDifferential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

934PCirculating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)

Annals of oncology, 2016-10, Vol.27, p.vi269-vi269

2016

Volltextzugriff (PDF)

3D planning of irreversible electroporation treatment in pancreatic carcinoma: a use case

HPB (Oxford, England), 2018-09, Vol.20, p.S661-S661

2018

Volltextzugriff (PDF)

Re: Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression across the Germ Cell Malignancy Spectrum

The Journal of urology, 2020-05, Vol.203 (5), p.884-884

Richie, Jerome P

2020

Volltextzugriff (PDF)

An augmented reality navigation system for laparoscopic liver surgery – First experiences

HPB (Oxford, England), 2018-09, Vol.20, p.S265-S266

2018

Volltextzugriff (PDF)

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

Annals of oncology, 2016-10, Vol.27, p.vi270-vi270

2016

Volltextzugriff (PDF)

909PPlasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nature communications, 2024-02, Vol.15 (1), p.1828-1828, Article 1828

2024

Volltextzugriff (PDF)

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

Annals of oncology, 2016-10, Vol.27, p.vi291-vi291

2016

Volltextzugriff (PDF)

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Canadian Urological Association journal, 2018-02, Vol.12 (2), p.E47-52

2018

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(73)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(30)
Science & Technology
(30)
Life Sciences & Biomedicine
(26)
Male
(21)
Middle Aged
(19)
Female
(17)
Aged
(16)
Oncology
(14)
Aged, 80 And Over
(11)
Adult
(9)
Antineoplastic Agents - Therapeutic Use
(7)
Urology
(7)
Biomarkers
(6)
Hematology, Oncology And Palliative Medicine
(6)
Sensitivity And Specificity
(6)
Urothelial Carcinoma
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Cancer
(5)
Carcinoma, Transitional Cell - Drug Therapy
(5)
Carcinoma, Transitional Cell - Pathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Editorial: Therapies and influences in urothelial carcinoma

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis

2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

The Future of Systemic Therapies for Localised Prostate Cancer

Stereotactic navigation versus ultrasound guidance in placing IRE applicators in a liver phantom

Palliative Radiotherapy Improves Pain and Reduces Functional Interference in Patients with Painful Bone Metastases: A Quality Assurance Study

PO-1205: Small cell carcinoma of the bladder: Retrospective long-term outcomes of chemoradiation

Utilization of Radiotherapy for Palliation of Bone Metastases: A 3-Year Patterns of Practice Study at a Regional Cancer Centre

Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371

983PDifferential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

934PCirculating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)

3D planning of irreversible electroporation treatment in pancreatic carcinoma: a use case

Re: Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression across the Germ Cell Malignancy Spectrum

An augmented reality navigation system for laparoscopic liver surgery – First experiences

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

909PPlasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Suchergebnisse filtern